Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Molecular and Cellular Endocrinology|May 16, 2021
Regulation of aromatase expression: Potential therapeutic insight into breast cancer treatmentDeborah Molehin, Stephanie Filleur, Kevin Pruitt
International Urology and Nephrology|July 3, 2007
Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapyThomas Nelius, Tobias Klatte, Werner de Riese, et al.
Renal Failure|November 16, 2012
The clinical usefulness of nuclear matrix protein-22 in patients with end-stage renal disease and microscopic hematuriaBrandon Trojan, Andrew Tang, Jason Chandrapal, et al.
Medical Oncology (Northwood, London, England)|April 15, 2009
Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapyThomas Nelius, Tobias Klatte, Werner de Riese, et al.
Medical Science Monitor Basic Research|March 22, 2019
Effect of Serum Deprivation Stress on Signal Induction Regulatory Protein-Alpha (SIRP-Alpha)-Mediated Erythrophagocytosis by MacrophagesZakaria Hindi, AbdAllah Gad, Courtney Jarvis, et al.
BJU International|April 13, 2007
Evaluation of peri-operative peripheral and renal venous levels of pro- and anti-angiogenic factors and their relevance in patients with renal cell carcinomaTobias Klatte, Malte Böhm, Thomas Nelius, et al.
BJU International|August 24, 2006
A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancerThomas Nelius, Tobias Klatte, Ron Yap, et al.
The Journal of Experimental Medicine|June 9, 2004
Nuclear factor of activated T cells balances angiogenesis activation and inhibitionTetiana A Zaichuk, Emelyn H Shroff, Rebekah Emmanuel, et al.
International Urology and Nephrology|July 15, 2017
Novel porcine model for calcium oxalate stone formationBrandon P Trojan, Sara J Trojan, Andrew Navetta, et al.
Onkologie|October 27, 2005
Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancerThomas Nelius, Frank Reiher, Tobias Lindenmeir, et al.
Pageof 2